# LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma

> **NCT03674463** · PHASE1 · UNKNOWN · sponsor: **Second Affiliated Hospital of Xi'an Jiaotong University** · enrollment: 10 (estimated)

## Conditions studied

- Refractory or Relapsed Multiple Myeloma

## Interventions

- **DRUG:** LCAR-B4822M CAR-T Cell Immunotherapy

## Key facts

- **NCT ID:** NCT03674463
- **Lead sponsor:** Second Affiliated Hospital of Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-26
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2018-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03674463

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03674463, "LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03674463. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*